Logo image of ADAP

ADAPTIMMUNE THERAPEUTICS-ADR (ADAP) Stock Fundamental Analysis

NASDAQ:ADAP - Nasdaq - US00653A1079 - ADR - Currency: USD

0.081  +0 (+0.87%)

Fundamental Rating

2

Taking everything into account, ADAP scores 2 out of 10 in our fundamental rating. ADAP was compared to 553 industry peers in the Biotechnology industry. ADAP has a bad profitability rating. Also its financial health evaluation is rather negative. ADAP is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

ADAP had negative earnings in the past year.
In the past year ADAP has reported a negative cash flow from operations.
ADAP had negative earnings in each of the past 5 years.
In the past 5 years ADAP reported 4 times negative operating cash flow.
ADAP Yearly Net Income VS EBIT VS OCF VS FCFADAP Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -50M -100M -150M

1.2 Ratios

ADAP has a Return On Assets of -44.22%. This is comparable to the rest of the industry: ADAP outperforms 53.71% of its industry peers.
Industry RankSector Rank
ROA -44.22%
ROE N/A
ROIC N/A
ROA(3y)-39.8%
ROA(5y)-36.38%
ROE(3y)-362.62%
ROE(5y)-240.54%
ROIC(3y)N/A
ROIC(5y)N/A
ADAP Yearly ROA, ROE, ROICADAP Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -100 -200 -300 -400 -500

1.3 Margins

ADAP's Gross Margin of 99.07% is amongst the best of the industry. ADAP outperforms 98.73% of its industry peers.
The Profit Margin and Operating Margin are not available for ADAP so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 99.07%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ADAP Yearly Profit, Operating, Gross MarginsADAP Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -2K -4K -6K -8K -10K

More info and screens

1

2. Health

2.1 Basic Checks

ADAP does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for ADAP has been increased compared to 1 year ago.
Compared to 5 years ago, ADAP has more shares outstanding
Compared to 1 year ago, ADAP has a worse debt to assets ratio.
ADAP Yearly Shares OutstandingADAP Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M
ADAP Yearly Total Debt VS Total AssetsADAP Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

2.2 Solvency

Based on the Altman-Z score of -9.50, we must say that ADAP is in the distress zone and has some risk of bankruptcy.
ADAP's Altman-Z score of -9.50 is on the low side compared to the rest of the industry. ADAP is outperformed by 72.51% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -9.5
ROIC/WACCN/A
WACC9.23%
ADAP Yearly LT Debt VS Equity VS FCFADAP Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M 300M

2.3 Liquidity

ADAP has a Current Ratio of 2.02. This indicates that ADAP is financially healthy and has no problem in meeting its short term obligations.
ADAP's Current ratio of 2.02 is on the low side compared to the rest of the industry. ADAP is outperformed by 75.77% of its industry peers.
ADAP has a Quick Ratio of 1.79. This is a normal value and indicates that ADAP is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Quick ratio, with a value of 1.79, ADAP is doing worse than 77.58% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 2.02
Quick Ratio 1.79
ADAP Yearly Current Assets VS Current LiabilitesADAP Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

More info and screens

6

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 76.47% over the past year.
The Revenue has grown by 878.48% in the past year. This is a very strong growth!
The Revenue has been growing by 175.59% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)76.47%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-5.56%
Revenue 1Y (TTM)878.48%
Revenue growth 3Y207.05%
Revenue growth 5Y175.59%
Sales Q2Q%28.3%

3.2 Future

The Earnings Per Share is expected to grow by 38.30% on average over the next years. This is a very strong growth
ADAP is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 9.16% yearly.
EPS Next Y-146.68%
EPS Next 2Y-15.71%
EPS Next 3Y-13.45%
EPS Next 5Y38.3%
Revenue Next Year-72.08%
Revenue Next 2Y-38.1%
Revenue Next 3Y-12.33%
Revenue Next 5Y9.16%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
ADAP Yearly Revenue VS EstimatesADAP Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 100M 200M 300M
ADAP Yearly EPS VS EstimatesADAP Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 0 0.5 -0.5 -1

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

ADAP reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ADAP. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ADAP Price Earnings VS Forward Price EarningsADAP Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ADAP Per share dataADAP EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 0.4 -0.4 0.6

4.3 Compensation for Growth

ADAP's earnings are expected to decrease with -13.45% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-15.71%
EPS Next 3Y-13.45%

More info and screens

0

5. Dividend

5.1 Amount

ADAP does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ADAPTIMMUNE THERAPEUTICS-ADR

NASDAQ:ADAP (8/1/2025, 3:09:57 PM)

0.081

+0 (+0.87%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-13 2025-05-13/bmo
Earnings (Next)08-11 2025-08-11/bmo
Inst Owners44.26%
Inst Owner Change-0.06%
Ins Owners0.35%
Ins Owner Change0%
Market Cap21.47M
Analysts74.29
Price Target1.47 (1714.81%)
Short Float %8.85%
Short Ratio1.2
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-49.97%
Min EPS beat(2)-75.07%
Max EPS beat(2)-24.87%
EPS beat(4)2
Avg EPS beat(4)105.18%
Min EPS beat(4)-75.07%
Max EPS beat(4)428.3%
EPS beat(8)2
Avg EPS beat(8)11.68%
EPS beat(12)5
Avg EPS beat(12)18.09%
EPS beat(16)6
Avg EPS beat(16)-5.76%
Revenue beat(2)1
Avg Revenue beat(2)-13.34%
Min Revenue beat(2)-42.36%
Max Revenue beat(2)15.67%
Revenue beat(4)3
Avg Revenue beat(4)102.41%
Min Revenue beat(4)-42.36%
Max Revenue beat(4)258.91%
Revenue beat(8)3
Avg Revenue beat(8)24.8%
Revenue beat(12)6
Avg Revenue beat(12)105.48%
Revenue beat(16)8
Avg Revenue beat(16)80.24%
PT rev (1m)-8.37%
PT rev (3m)-15.35%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-9.14%
EPS NY rev (1m)0%
EPS NY rev (3m)-64.11%
Revenue NQ rev (1m)0.17%
Revenue NQ rev (3m)19.01%
Revenue NY rev (1m)0.8%
Revenue NY rev (3m)29.4%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.12
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.2
EYN/A
EPS(NY)-0.25
Fwd EYN/A
FCF(TTM)-0.42
FCFYN/A
OCF(TTM)-0.41
OCFYN/A
SpS0.68
BVpS-0.14
TBVpS-0.16
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -44.22%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 99.07%
FCFM N/A
ROA(3y)-39.8%
ROA(5y)-36.38%
ROE(3y)-362.62%
ROE(5y)-240.54%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover1.14
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 32.82%
Cap/Sales 1.98%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.02
Quick Ratio 1.79
Altman-Z -9.5
F-Score3
WACC9.23%
ROIC/WACCN/A
Cap/Depr(3y)187.66%
Cap/Depr(5y)146.98%
Cap/Sales(3y)39.72%
Cap/Sales(5y)67.08%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)76.47%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-5.56%
EPS Next Y-146.68%
EPS Next 2Y-15.71%
EPS Next 3Y-13.45%
EPS Next 5Y38.3%
Revenue 1Y (TTM)878.48%
Revenue growth 3Y207.05%
Revenue growth 5Y175.59%
Sales Q2Q%28.3%
Revenue Next Year-72.08%
Revenue Next 2Y-38.1%
Revenue Next 3Y-12.33%
Revenue Next 5Y9.16%
EBIT growth 1Y74.79%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-99.04%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y25.63%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y13.48%
OCF growth 3YN/A
OCF growth 5YN/A